Athira pharma highlights strong execution of strategy and positioning for the future

Bothell, wash., march 30, 2022 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today issued the following statement in response to the release from richard kayne:

ATHA Ratings Summary

ATHA Quant Ranking